About Us

What began as two families fighting for their daughters' futures has grown into a national movement — one that’s rewriting what’s possible for children with de novo SPG4.

In little more than two years, we’ve united families, scientists, and industry leaders. We’ve hosted three NIH and Boston Children’s Hospital-partnered scientific symposia, launched a global support network, and funded multiple research initiatives — including a gene therapy program now advancing toward clinical trials.

Our most recent fundraiser gathered 130 golfers, over 200 dinner guests, and raised more than $110,000 in a single night.

Today, The Lilly and Blair Foundation is a driving force in de novo SPG4 research, funding, and awareness.

Our Mission
Our mission is to accelerate research toward treatments and a cure for childhood-onset, de novo SPG4 by funding innovative science, connecting families and researchers, and building a future full of hope for those impacted by this devastating disease.

Please join the fight as we work to rewrite the future for these incredible children.

The Faces of Childhood-Onset, De Novo SPG4

LEADING THE CHARGE AGAINST
DE NOVO SPG4

We’re not just raising awareness — we’re accelerating treatments.
The Lilly and Blair Foundation is the only nonprofit solely focused on de novo SPG4. We’re leading with urgency, funding research others haven’t touched, and connecting families to the scientists shaping what’s next.

People are turning to us — not just for our story, but for our strategy.

  • May 2024 - Launched monthly virtual support group meetings with other SPAST c.1496G>A, p.Arg499His families

  • June 2024 - Hosted our second annual Golf Tournament and Dinner (view photos and remarks)

  • July 2024 - Provided $150,000 in funding to Boston Children’s Hospital, UMass Chan Medical Center and the University of Wisconsin to be used toward the first 3 aims of the AAV9 Vector Gene Therapy Project for SPG4

  • November 2024 – Participated in the UltraGenyx Rare Disease Bootcamp, held in Novato, CA.

  • December 2024 - Hosted the 3rd Annual Scientific Symposium on SPG4 with Boston Children’s Hospital

  • February 2025 - Funded The Baas Lab at Drexel University to help them continue exploring ways to restore lost function in children already experiencing symptoms

  • March 2025 - Funded the Liang Lab at Drexel University to help them continue their research on SPG4 patient-derived hiPSC models.

  • March 2025 - Invited to speak at the Annual Meeting of TreatHSP and the Tom Wahlig Foundation. View the agenda here.

  • May 2025 - Hosted our third annual Golf Tournament and Dinner raising $110,000 for de novo SPG4. View photos and remarks.

Medical Advisory Board

  • Darius Ebrahimi-Fakhari, MD, PhD

    DIRECTOR, MOVEMENT DISORDERS PROGRAM AND ATTENDING, DEPARTMENT OF NEUROLOGY, BOSTON CHILDREN’S HOSPITAL; ASSISTANT PROFESSOR OF NEUROLOGY, HARVARD MEDICAL SCHOOL

    Dr. Ebrahimi-Fakhari is a child neurologist and neuroscientist with special expertise in childhood-onset neurogenetic, neurodegenerative, and movement disorders. His translational research includes The Registry and Natural History Study for Early-Onset Hereditary Spastic Paraplegia.


  • Ariane Soldatos, MD, MPH

    DIRECTOR, PEDIATRIC NEUROLOGY CONSULTATION SERVICE, NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) AND PHYSICIAN SCIENTISTS, UNDIAGNOSED DISEASES PROGRAM, NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI), NATIONAL INSTITUTES OF HEALTH (NIH)

    Dr. Soldatos' research interests include genomics and clinical trials for rare diseases. She is associate investigator on first-in-human clinical trials including gene therapy for rare childhood neurodegenerative diseases.

  • Matthew Elrick, MD, PhD

    ASSISTANT PROFESSOR OF NEUROLOGY, THE JOHNS HOPKINS HOSPITAL.

    Dr. Elrick specializes in the care of children with neuromuscular disorders, and EMG studies in children and adults. He has special interests in genetic neuromuscular and neurodegenerative disorders and Acute Flaccid Myelitis.







Scott Chilson

Jay Coonan

Board of Directors

Katie Gregg

Chris Lorek

Stephanie Lorek

Michael Gregg

Industry Partners

The Lilly and Blair Foundation is proud to be part of the NORD’ RareAction Network and the Global Genes Advocacy Alliance, both of which advocate for equitable access to timely diagnosis, treatment, and care for rare diseases. Through these networks, we work to raise awareness, provide community support, advance research, and address the specific needs of individuals affected by rare diseases worldwide, aiming to improve outcomes and quality of life on a global scale.

SPG4 Alliance Partners

Together We Can

Time is not on our side, but we hope you will be.